The efficacy and safety of vitamin D supplementation for the treatment of NAFLD/NASH
Not Applicable
Recruiting
- Conditions
- AFLD/NASH
- Registration Number
- JPRN-UMIN000017150
- Lead Sponsor
- ippon Medical School Chiba Hokusoh Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1.pregnant woman or lactating mother 2.poorly controlled heart failure 3.poorly controlled diabetes or hypertension 4.evere renal disorder 5.decompensated liver cirrhosis 6.other liver diseases, including autoimmune hepatitis, primary biliary cirrhosis and alcoholic hepatitis, liver failure 7.positive result for hepatitis C antibody, hepatitis B surface antigen and antibody to human immunodeficiency virus type-1 8.hypercarcemia 9.hyperparathyroidism 10.medication with other vitamin preparations 11.Judged by investigator not to be appropriate for inclusion in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The liver function and the degree of liver fibrosis after vitamin D supplementation for 48weeks
- Secondary Outcome Measures
Name Time Method 1.The lipid and glycometabolism after vitamin D supplementation for 48weeks 2.The safety of vitamin D supplementation